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SUMMARY
A rare germline duplication upstream of the bone
morphogenetic protein antagonist GREM1 causes
a Mendelian-dominant predisposition to colorectal
cancer (CRC). The underlying disease mechanism is
strong, ectopic GREM1 overexpression in the intes-
tinal epithelium. Here, we confirm that a common
GREM1 polymorphism, rs16969681, is also associ-
atedwith CRC susceptibility, conferring20%differ-
ential risk in the general population.We hypothesized
the underlying cause to be moderate differences
in GREM1 expression. We showed that rs16969681
lies in a region of active chromatin with allele- and
tissue-specific enhancer activity. The CRC high-risk
allele was associated with stronger gene expression,
and higherGrem1mRNA levels increased the intesti-
nal tumor burden in ApcMin mice. The intestine-spe-
cific transcription factor CDX2 and Wnt effector
TCF7L2 bound near rs16969681, with significantly
higher affinity for the risk allele, and CDX2 overex-
pression in CDX2/GREM1-negative cells caused re-
expression of GREM1. rs16969681 influences CRC
risk through effects on Wnt-driven GREM1 expres-
sion in colorectal tumors.
INTRODUCTION
Bonemorphogenetic proteins (BMPs) are critical for normal intes-
tinal homeostasis, counteracting Wnt signaling toward the top of
crypts, and allowing differentiation (Scoville et al., 2008). BMP
antagonists, notably GREM1, are expressed in the mesenchyme
at the crypt base, restricting BMP activity, potentiating Wnt
signaling, and maintaining the epithelial stem cell compartment.
Germline mutations in BMP pathway members occur in juvenile
polyposis and hereditary mixed polyposis (HMPS) (Hardwick
et al., 2008; Jaeger et al., 2008). HMPS is a rare, autosomal-domi-
nant condition in which patients develop multiple types of
colorectal polyp and cancer. HMPS results from a 40 kb duplica-
tion upstream of GREM1, which causes dramatically increased,
ectopic GREM1 expression in the normal epithelium (Jaeger
et al., 2012). In the general population, moreover, single-nucleo-
tide polymorphisms (SNPs) near BMP pathway genes have been
found by genome-wide association studies to predispose to colo-
rectal cancer (CRC) (Jaeger et al., 2012; Tomlinson et al., 2011).
rs4779584, near GREM1, was one of the first CRC SNPs to
be found. Interestingly, rs4779584 does not show an association
with predisposition to benign colorectal tumors (Carvajal-Car-
mona et al., 2013), suggesting that it may act after tumor initiation.
To uncover functional variation tagged by rs4779584, we had
previously refined its association signal using direct genotyping,
imputation, and conditional logistic regression (Tomlinson et al.,
2011). This analysis suggested that rs4779584 captured two inde-
pendent association signals represented by SNPs rs16969681
and rs11632715 upstream of GREM1. In this study, we aimed
to identify the functional variation tagged by rs16969681 and
characterize the mechanism whereby it influenced CRC risk.
RESULTS AND DISCUSSION
rs16969681 Lies in a Region with Features of an
Enhancer Element
An updated genetic fine-mapping analysis of SNPs upstream of
GREM1 using current SNP reference panels confirmed the exis-
tence of two independent CRC risk SNPs (details not shown).
One of the signals was still represented by rs16969681. Other
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SNPs in strong linkage disequilibrium (LD) with rs16969681
showed an20-fold lower likelihood of association with disease
(Table S1). Because rs16969681 tags SNPs in intergenic DNA, its
association is most likely caused by modifying a gene regulatory
element.We therefore investigated theepigenetic characteristics
of the rs16969681 region (Figure 1). ENCODE shows an area of
DNase hypersensitivity and transcription factor binding close to
rs16969681. However, the cell lines used in these studies are
not of intestinal origin, so we wished to expand these studies in
appropriate cell types. AlthoughGREM1 is principally expressed
by mesenchymal cells in normal intestine, we found GREM1
mRNA in 11/32CRCcell lines (CRCCLs), which are all of epithelial
origin (Figure S1). We therefore performed formaldehyde-assis-
ted identification of regulatory elements (FAIRE) in four CRCCLs
to identify areas of nucleosome-depleted chromatin in the 25 kb
region upstream of the GREM1 promoter, including rs4779584
and rs16969681. The highest signal in GREM1-expressing lines
was a 1.3 kb peak centered on rs16969681 (Figure 1B). Chro-
matin immunoprecipitation (ChIP) using antibodies against
H3K4Me2 (marker of promoters and enhancers) and panH4Ac
(marker of active chromatin) also showed signals at rs16969681
and the GREM1 transcription start site (TSS), specifically in
GREM1-expressing lines (Figures 1C and 1D). The chromatin
signature was indicative of a regulatory element, probably an
enhancer, located at or near rs16969681. In support of this,
we demonstrated an interaction between the region containing
rs16969681 and GREM1’s promoter using chromosome confor-
mation capture (Jaeger et al., 2012; Figure S2).
Figure 1. Chromatin Profiling Upstream of GREM1
(A) Diagram showing position on chromosome 15 and the main features in the 25 kb region upstream of the promoter, TSS, and transcribed region of GREM1
(chr15:32.9–33.025 Mb; hg37), including exons (green boxes) and SNPs (black marks). Regional interspecific conservation (University of California, Santa Cruz
phyloP100way all [vert.]), DNase1 hypersensitivity (wgEncodeRegDnaseClustered V2), and TF-binding (wgEncodeReg TfbsClustered V3) sites are also shown in
the bottom panel. TFs that bind at or adjacent to rs16969681 in ENCODE nonintestinal cell lines include HDAC2, BHLHE40, FOXA1, FOXA2,MAFK, HNF4G, SP1,
RXRA, GATA3, MYBL2, p300, HNF4A, and TCF7L2.
(B) FAIRE assay on four CRCCLs: LS180 (GREM1-high; rs16969681 C/C), C99 (GREM1-high; T/T), HCC56 (GREM1-low; T/T), and SW48 (GREM1 null; C/C). The
graph shows relative enrichment at each primer set as determined by the DDCt method, first by using noncrosslinked genomic DNA to normalize the results from
nucleosome-depleted DNA and then by expressing each primer set relative to primers at chr15:32,993,925, telomeric to the rs16969681 signal.
(C and D) ChIP assays with anti-H3K4Me2 and anti-H4Ac antibodies, respectively, analyzed by SYBR green qPCR on four CRC cell lines as in (B). Relative
enrichment was determined by the DDCt method using sonicated input DNA to normalize the values from immunoprecipitated DNA and expressing this ratio
relative to that seen at the Rhodopsin promoter as a negative control.
(B), (C), and (D) all show an area of active chromatin in the region surrounding rs16969681 with rs16969862 at its telomeric edge. Chromatin at rs4779584 shows
no enrichment for activating marks. See also Table S1 and Figures S1 and S2.
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The rs16969681 Enhancer Regulates Gene Expression
in an Allele-Specific Manner
We next determined whether the rs16969681 genotype influ-
enced GREM1 mRNA. rs16969344, a SNP in perfect LD with
rs16969681, was not associated with total GREM1mRNA levels
in The Cancer Genome Atlas CRC samples. However, differ-
ences in gene-expression levels among cancers may have
many different causes, and we therefore searched for allele-spe-
cific expression (ASE) differences. One CRCCL in our panel
(COLO320) was heterozygous at rs16969681, had two copies of
chromosome 15q, expressed GREM1, and was heterozygous
for a suitable SNP in the GREM1 transcript (rs7162202 in the
30 UTR). We found that the normalized allelic ratio (G:T) of
rs7162202 in COLO320 cDNA was 1.62 (p = 0.001; Figure 2A)
compared with 1.1 (p = 0.11) in a control CRCCL homozygous
for rs16969681 (SW403), consistent with ASE in COLO320.
Due to the large distance (>30 kb) between rs16969681 and
rs7162202 and no suitable cell line for copy-number-based
phasing, we could not determine whether the high-risk allele
wasassociatedwithhigherexpression incis.We thereforecarried
Figure 2. Allele-Specific Effects of an Enhancer at rs16969681
(A) rs16969681 heterozygote COLO320 shows allele-specific expression of GREM1. cDNA isolated from COLO320 cells was analyzed to measure ASE of SNP
rs7162202 (GREM1 30 UTR). The chart shows the results after normalization with COLO320 genomic DNA. There was a mean G/T ratio of 1.62 (p = 0.001; t test).
rs16969681 homozygous cell line SW403 showed a normalized ratio of 1.13 (p = 0.11).
(B) Luciferase reporter assays to analyze the enhancer activity of 1.0–4.1 kb fragments containing rs16969681 upstream of GREM1 using the pGL3 promoter
vector in SW948 cells. Scale diagrams are drawn for each fragment. Green arrows represent the low-risk and red arrows the high-risk allele. The bar chart shows
the average luciferase activity of triplicate experiments normalized using the pGL4 Renilla activity and expressed relative to pGL3 containing a neutral stretch of
DNA (control). The high-risk allele causes a significant increase in enhancer activity (p < 0.0002). The smallest (1.4 kb) fragment containing rs16969681 shows high
activity, which is increased nearly 2-fold in the presence of the risk allele (p = 0.029).
(C) Box plot showing significant reduction in polyp numbers in Grem1+/;ApcMin/+ mice compared to Grem1+/+;ApcMin/+ littermates. In the former, mean polyp
number at 5 to 6 months was 18 (n = 5; SD = 4.4); in the latter, mean polyp number was 43 (n = 9; SD = 22; p = 0.0162; Wilcoxon test).
(D) Gastrointestinal expression of a rs16969681-LacZ reporter construct. Intestines and stomachs were removed from transient transgenic mice (16 dpc). The
upper panels show b-galactosidase expression in the reporter animal (i), but not in wild-type controls (ii). The lower panels show anti-b-galactosidase immu-
nofluorescence (red). Reporter expression is present in both the mesenchymal (lower) and epithelial compartments (upper) of the intestine in transgenic mice (iii),
but not their wild-type littermates (iv).
Error bars represent SEM.
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Figure 3. CDX2 Binding at rs16969681 in GREM1-Expressing CRCCLs and Its Effect on GREM1 Expression
(A) ChIP assays with anti-CDX2 and anti-TCF7L2 antibodies analyzed by SYBR green qPCR on a number of CRC cell lines (C99 T/T, LS180 C/C, SW1222 C/T,
SW48C/C, and SW948 C/C). The graphs show enrichment around rs16969681 inGREM1-expressing cell lines irrespective of genotype. Relative enrichment was
determined by the DDCt method, using sonicated input DNA to normalize the enrichment seen in immunoprecipitated DNA and then expressing each primer set
relative to primers at chr15: 32,993,925. Despite repeated attempts, COLO320 (C/T) chromatin did not immunoprecipitate efficiently enough for use in ChIP
assays.
(B) Sanger sequence traces of input, CDX2 ChIP, and TCF7L2 ChIP output from SW1222 highlighting rs16969681. A bias toward the risk T allele (red) at
rs16969681 in the ChIP output is not seen in the input. This was confirmed by formal allele counting.
(C) Luciferase reporter assays to analyze the enhancer activity of GREM1 upstream fragments containing the 1.4 kb around rs16969681 cloned into pGL3
promoter vector carried out in SW948 cells. Green arrows represent the low-risk alleles and red arrows the high risk. Black squares denote CDX2 core-binding
motifs. The graph shows the average luciferase activity of three experiments (where each construct was analyzed in triplicate) normalized using the pGL4 Renilla
activity and expressed relative to pGL3 promoter containing a neutral stretch of DNA (control). Deletion of a 71 bp EcoR1/ZraI fragment removing rs16969681 and
disrupting bases adjacent to CDX2-binding motifs caused a significant reduction in enhancer activity.
(D) CDX2 overexpression experiment to analyze the effect on endogenousGREM1mRNA expression. TwoCMV-CDX2 expression plasmids and an empty vector
were each transfected in triplicate into the SW480 CRCCL, chosen for its low endogenousCDX2 andGREM1 expression and its consistently high levels of CDX2
(legend continued on next page)
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out luciferase reporter assays to investigate allele-specific
enhancer activity of the rs16969681 region in vitro in SW948 cells
(Figure 2B). Constructs containing the low-risk allele showed
moderate enhancing activity, but this was significantly increased
when rs16969681 was mutated to the high-risk allele (p < 0.001).
A series of deletion constructs around rs16969681 showed
increasing enhancer activity (Figure 2B). The smallest construct,
with the greatest enhancer activity, showed rs16969681’s high-
risk allele to have almost double the activity of the low-risk
allele (p = 0.029). Deletion of the rs16969681 region, leaving
rs16969862 alone, showed no enhancing effect. Thus, we found
that the region containing rs16969681 carries the hallmarks of
an allele-specific transcriptional enhancer.
Grem1 Levels Modify Intestinal Tumorigenesis in Mice
We wished to test whether modest changes in GREM1 levels,
such as those resulting from the rs16969681 genotype, could
affect intestinal tumorigenesis in vivo. Because the region around
rs16969681 is not highly conserved, we used constitutionally
heterozygous Grem1+/ mice (Gazzerro et al., 2007) as a model
for the effects of rs16969681. We confirmed that these animals
had 50% reduced Grem1 mRNA expression relative to wild-
type mice and showed no intestinal abnormalities or polyposis
phenotype. Grem1+/;ApcMin/+ animals had a >50% reduction in
adenomas compared with their well-characterized Grem1+/+;
ApcMin/+ littermates (p = 0.0162; Wilcoxon test; Figure 2C; Su
et al., 1992). We examined tumors from littermates for differences
in proliferation (Ki67 immunohistochemistry), apoptosis (Casp3),
Wnt signaling (b-catenin), stemcell numbers (Sox9), andcanonical
BMP pathway activity (phospho-Smad1,5,8). We observed
increased apoptosis in Grem1+/;ApcMin/+ tumors (p = 0.044; n =
12; t test) andnoother differences between themouse genotypes.
The rs16969681 Enhancer Shows Tissue-Specific
Activity In Vivo
In order to confirm that the rs16969681 enhancer is functional
in vivo, we generated transgenic mice carrying a 2 kb fragment
containing rs16969681 upstream of a LacZ reporter gene.
b-galactosidase expression was found specifically in the intes-
tines and stomach andwas absent fromother tissues (Figure 2D).
Interestingly, reporter expression was seen in both mesen-
chymal and epithelial cells of the intestine (Figure 2Diii), though
GREM1 is not normally expressed in the epithelium. This sug-
gests an epithelial role for the enhancer.
CDX2 and TCF7L2 Bind the Enhancer in an Allele-
Specific Fashion and CDX2 Drives GREM1 Expression
Next, we sought to identify the mechanism by which rs16969681
genotype could modify enhancer activity by identifying tran-
scription factors (TFs) that bound to the surrounding region.
We used biotin-labeled electrophoretic mobility shift assay
probes, a development of Butter et al. (2012) to pull down
DNA-protein complexes from SW948 and C99 nuclear extracts,
followed by quantitative mass-spectrometry (N.C.H., L.N.N.,
N.C. Hornig, and H.G.S., unpublished data). We combined these
data, in silico predictions fromBiobase/TRANSFAC in a 50 bp re-
gion around rs16969681, and mining of public ChIP sequencing
(ChIP-seq) databases (Mokry et al., 2010; Verzi et al., 2010) to
generate a list of candidate TFs. We assessed these proteins
using ChIP in GREM1-expressing cells (C99 rs16969681 T/T,
LS180 C/C, SW1222 C/T, and SW948 C/C) and a nonexpressing
line (SW48 C/C). CDX2 and TCF7L2 (also known as TCF4) bound
to the rs16969681 region (Figure 3A), as did p300, RUNX1, and,
less reliably, HNF4A (Figure S3). TCF7L2, HNF4A, and p300 are
also listed as binding in published ENCODE data.
In order to investigate allele-specific TF binding, we quantified
rs16969681 alleles in the ChIP output from the heterozygous cell
line SW1222. p300 and RUNX1 showed no evidence of allele-
specific binding (p > 0.5). HNF4A binding was not present in all
heterozygous cell lines. However, CDX2 (odds ratio [OR] = 4.7;
p = 0.001; n = 81; Fisher’s exact test) and TCF7L2 (OR = 2.0;
p = 0.028; n = 63) showed a significant bias toward the risk allele
(Figure 3B). We also found a correlation between GREM1 and
CDX2 mRNA expression in our panel of CRC cell lines (p =
0.0088; n = 34; Spearman’s rank correlation). These data again
indicate that the enhancer at rs16969681 is important in cells
of epithelial origin.
The core consensus CDX2-binding motif, ATAAA (Verzi et al.,
2010), occurs both 14 bp upstream and 65 bp downstream of
rs16969681. To confirm that the CDX2-binding region of the
rs16969681 enhancer is important for its activity, we deleted a
71 bp fragment from our luciferase reporter constructs (Fig-
ure 2B), removing rs16969681 and disrupting the bases adjacent
to the core CDX2-binding motifs. Figure 3C shows the resultant
significant reduction in enhancer activity and loss of allele-spe-
cific expression in SW948 cells. To demonstrate that CDX2
protein can directly regulate GREM1 transcription, we overex-
pressed CDX2 in SW480, a CRCCL with low endogenous
CDX2 and GREM1. We achieved consistent CDX2 overex-
pression using two separate constructs, causing an 3.5-fold
increase in GREM1 expression (p = 0.0005; Figure 3D). By com-
parison, in cell lines with already high levels of GREM1 or CDX2,
no effect or less consistent results were seen.
Epithelial GREM1 Expression Occurs in Sporadic
Colorectal Adenomas
Several lines of evidence presented above suggest that the
rs16969681 genotype might have its effects in dysplastic colo-
rectal epithelium, that is, at a stage after tumor initiation (Carva-
jal-Carmona et al., 2013). We noted that CDX2 expression
following transfection (confirmedbybothqRT-PCRandwesternblot).mRNAwasextractedandanalyzedbyTaqman, also in triplicate. Thechart shows the relative
expression of GREM1 mRNA in the overexpression samples compared to empty vector calculated using the DDCt method, normalized to GAPDH. Each over-
expression plasmid individually caused a similar 3.5-fold increase in GREM1 expression. The chart shows the combined results from both (p = 0.0005; t test).
(E)GREM1 expression in three sporadic adenomas relative to paired normal tissue. Two to six crypts were isolated from each sample and mRNA levels analyzed
by Taqman qRT-PCR. The chart shows relative GREM1 levels calculated by DDCt, normalized to GAPDH. Adenomas had a mean of 10.3 times more GREM1
mRNA than paired normal crypts (p = 0.006; t test).
See also Figure S3. Error bars represent SEM.
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occurs in almost all colorectal adenomas but is lost in some
CRCs (Qualtrough et al., 2002), and we therefore wondered
whether GREM1 is expressed in adenomas as well as CRCs.
We assayed GREM1 mRNA expression in 15 isolated crypts
from three sporadic adenomas and found a 10-fold increase in
epithelial expression compared with surrounding normal epithe-
lial tissue (p = 0.002; ANOVA; Figure 3E).
Concluding Remarks and Proposed Model of GREM1
Regulation by CDX2 and TCF7L2 Binding to the
rs16969681 Enhancer
We have found that the GREM1 locus harbors at least two SNPs
that independently influence the risk of CRC. Studies of Grem1
expression in the developing limb bud (Zuniga et al., 2012)
have shown that proximal and distal global control regions
(GCRs) near GREM1 regulate gene expression in a complex
fashion. The SNP rs16969681 lies upstream of GREM1 in a re-
gion distinct from the known GCRs and is close to a regu-
latory element that we have shown to act as an allele-specific
GREM1 enhancer. Mouse models confirm that relatively modest
changes in Grem1 expression influence intestinal tumor burden,
possibly through variation in apoptosis. The rs16969681 region
differentially binds the intestine-specific TF CDX2 and the Wnt
effector TCF7L2. Both these transcription factors play important
roles in intestinal function and often co-occupy binding sites
(Verzi et al., 2010, 2013). CDX2 is described as a master TF
that establishes intestinal epithelial identity (Gao et al., 2009;
Qualtrough et al., 2002) and maintains open chromatin (Verzi
et al., 2013) for TFs such as TCF7L2. Although further investiga-
tion is required, we hypothesize (Figure 4) that, with the possible
exception of the stem cell compartment, CDX2 allows TCF7L2 to
act as repressor in the Wnt-low environment of the normal
epithelium. However, with high levels of Wnt, such as colorectal
tumors, TCF7L2 complexes with b-catenin and drives GREM1
expression, promoting tumorigenesis.
EXPERIMENTAL PROCEDURES
Detailed methodology is presented in Supplemental Information. All error bars
represent the SEM.
CRC Patients
Sample sets are those reported inWhiffin et al. (2013), plus UK2 and Scotland2
reported in Tomlinson et al. (2011).
Formaldehyde-Assisted Identification of Regulatory Elements
FAIRE was carried out using the method adapted from Giresi et al. (2007).
Briefly, 108 cells were crosslinked for 5 min with 1% formaldehyde, neutral-
ized, washed, and scraped. Uncrosslinked cells were used as a control. Cells
were lysed and the chromatin sonicated and extracted with phenol:chloro-
form. Purified DNA was analyzed by SYBR green quantitative PCR (qPCR)
using primers from Table S2.
Native ChIP
Native ChIP was carried out as previously described (Umlauf et al., 2004).
Approximately 108 cells were collected, washed in PBS, and lysed, and
chromatin was purified using a sucrose cushion. Chromatin was fragmented
with MNase1, and immunoprecipitation (H3K4Me2, 07-030 Millipore; H4Ac,
06-866 Millipore) was carried out overnight. Antibody complexes were
captured with protein A or G Dynabeads (Invitrogen) and washed. DNA
was eluted and purified. Purified DNA was analyzed by SYBR green
qPCR as above.
Crosslinked ChIP
Approximately 108 cells were crosslinked for 10 min with 1% formaldehyde,
neutralized, washed, and scraped. Cells were lysed and the chromatin
sonicated prior to overnight immunoprecipitation (anti-CDX2, Bethyl Labora-
tories; anti-TCF7L2, Santa Cruz). Antibody complexes were incubated with
protein A or G beads, washed, and eluted. Purified DNA was analyzed
by SYBR green qPCR as above. For allelic analysis, PCR products were
TA cloned using pGem TAeasy (Promega) followed by colony PCR and
sequencing.
Sequenom MassARRAY
For ASE analysis, genomic DNA and RNA were extracted from CRCCLs
COLO320 and SW403 and cDNA generated. Paired cDNA and genomic
DNA samples, in triplicate, were processed using the Iplex assay and detected
by Sequenom MALDI-TOF mass spectrometry. The products were run using
the Sequenom genotyping protocol, visualized using the MassARRAY Typer
4.0, and the areas under the curves used to calculate the allelic ratios of
each sample.
Luciferase Reporter Assays
Luciferase reporter assays were carried out as described (Jaeger et al., 2012).
Briefly, putative enhancer fragments in the pGL3 promoter vector (Promega)
were cotransfected into SW948 cells with 1/10 concentration of pGL4 Renilla
vector. Luciferase and Renilla activity wasmeasured using the Dual Luciferase
Assay system (Promega) and the Avent luminometer. Readings were normal-
ized and expressed relative to a control plasmid.
Transgenic Reporter Assays
All work was performed according to Spanish regulations for animal experi-
mentation and approved by the Consejo Superior de Investigaciones Cientif-
icas ethics committee. Two-kilobase constructs containing rs16969681 and
rs16969862, the minimal beta-globin promoter, LacZ, and a SV40 polyadeny-
lation signal were linearized, diluted to 5 ng/ml in microinjection buffer, and
used to inject fertilized mouse eggs from CBA/Ca 3 C57Bl/6 crosses. F0
embryos of 9.5–13 days postcoitum (dpc) stages and tissues from F0 animals
at postnatal day 1 (P1) and P35 were harvested. Embryos and dissected tis-
sues were fixed overnight, washed and placed in 10 ml of X-gal solution for
2–20 hr at 37C, and then postfixed.
ChIP-Seq Data Mining
CDX2 ChIP-seq data from CACO2 cells (Gene Expression Omnibus series
GSE23436; Verzi et al., 2010) and TCF7L2 data from LS147T cells (series
GSE18481; Mokry et al., 2010) were downloaded and mined for signals in
the GREM1 gene and surrounding region.
CDX2 Overexpression Assays
SW480 cells were plated out and transfected with CMVCDX2 (Addgene) and
CMVFLAG-CDX2 (Barros et al., 2011). Cells were lysed, RNA and cDNA gener-
ated, and CDX2 and GREM1 mRNA levels measured by quantitative RT-PCR
(qRT-PCR) using the Taqman system (Applied Biosystems).
Adenoma GREM1 mRNA Expression
Individual crypts from normal and adenomatous patient epithelium were iso-
lated as described previously (Jaeger et al., 2012) to ensure exclusion of any
pericryptal myofibroblasts. cDNA was generated and analyzed by qRT-PCR
as above.
Transgenic Mouse Crosses
Grem1+/flox mice, a kind gift of E. Canalis, were crossed with Pgk-Cre mice
to inactivate one copy of Grem1 in the germline. These mice were crossed
with ApcMin/+ mice to generate Grem1+/; ApcMin/+ and Grem1+/+; ApcMin/+
animals. Mice were aged for 5 to 6 months and litters sacrificed when one
member showed symptoms of intestinal tumors. Intestines were dissected,
fixed, and stained and polyps counted. All procedures were carried out in
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accordance with Home Office UK regulations and the Animals (Scientific Pro-
cedures) Act 1986. Mice were housed at the Functional Genomics Facility,
Wellcome Trust Centre for Human Genetics, Oxford.
Immunohistochemistry
Immunohistochemistry was performed as described in Jaeger et al. (2012)
using anti-CASP3 (R&D Systems).
Figure 4. Proposed Model of Action of CDX2 and TCF7L2 on GREM1 Expression through Binding Close to rs16969681
The model describes how the rs16969681 enhancer might regulate GREM1 transcription in (A) normal intestines and (B) adenomas based on the previously
proposed model of CDX2 acting as a pioneer TF for TCF7L2.
(A) The normal crypt is subjected to aWnt gradient with high levels at the base and low/absent levels at the neck. The top panel (blue) shows the situation for most
normal crypt epithelium cells. Here, CDX2 binds to the enhancer, partially disrupting the repressive chromatin, butWnt signaling, and therefore active b-catenin, is
at low or moderate levels, so the majority of TCF7L2 is bound by repressors such as Groucho (Cavallo et al., 1998; Roose et al., 1998). Allele-specific effects of
CDX2 binding are not apparent because GREM1 expression is at a very low basal level and essentially repressed. There is no enhancer activity. In the middle
panel,Wnt levels are higher, as for example in the stem cell zone at the crypt base. Here, activated TCF7L2/b-catenin complexes bind together with CDX2 and low
levels of enhancer activity result; this is consistent with evidence that intestinal stem cells produce low levels of secreted BMP antagonists (He et al., 2004). The
bottom panel (orange) shows the mesenchyme, where no CDX2 is present, although there are high levels of Wnt. GREM1 expression is activated by unknown
mesenchymal enhancers or mesenchyme-specific TFs binding at rs16969681.
(B) In the pathological setting of an adenoma, APC or CTNNB1mutations cause constitutive Wnt activation and high levels of Wnt target gene expression. CDX2
opens up the chromatin, allowing high levels of activated TCF7L2/b-catenin to cause GREM1 transcription. On the rs16969681 risk allele (bottom panel), extra
CDX2 binding results in higher enhancer activity. The downstream effects of the increased GREM1may include an increase in stem-like cells and angiogenesis.
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SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables and can be found with this article online at
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